MELIOR DISCOVERY INC

MELIOR DISCOVERY INC specializes in preclinical pharmacokinetic and toxicology testing services, delivering precise in vitro and in vivo data to support drug development pipelines. Their core expertise lies in conducting pharmacokinetic studies—analyzing absorption, distribution, metabolism, and excretion (ADME) profiles—using advanced analytical platforms such as LC-MS/MS and radiolabeled tracer techniques. The company provides critical early-stage data to inform dosing regimens, bioavailability assessments, and safety profiling, enabling sponsors to de-risk clinical translation. Their technical focus includes bioanalytical method validation, sample processing under GLP-like conditions, and data integrity protocols aligned with FDA and OECD guidelines, positioning them as a niche provider of high-quality preclinical pharmacology services for government-funded research. MELIOR DISCOVERY INC has demonstrated direct engagement with the Department of Health and Human Services, supporting research initiatives tied to public health drug development and therapeutic evaluation. The agency leverages their capabilities to generate non-clinical PK/PD datasets that inform regulatory decision-making and grant-funded biomedical projects, indicating a trusted partnership in advancing federally prioritized therapeutics. The contractor operates primarily within NAICS 541380, which encompasses specialized testing laboratories delivering analytical and preclinical services to pharmaceutical and biotech clients. Their market positioning centers on early-phase drug discovery support, serving federal research entities that require rigorous, reproducible pharmacokinetic data without the scale of large CROs. This niche focus distinguishes them in the preclinical services landscape. MELIOR DISCOVERY INC is a small business structured as a 2L entity, headquartered in Exton, Pennsylvania. While no formal government certifications are disclosed, their work adheres to industry standards for laboratory quality and data reliability. Their geographic presence is localized but strategically aligned with federal biomedical research hubs in the Mid-Atlantic region.